Literature DB >> 33121230

An Overview of Genetic Information of Latent Mycobacterium tuberculosis.

Faezeh Hamidieh1, Parissa Farnia2, Jamileh Nowroozi1, Poopak Farnia2,3, Ali Akbar Velayati2.   

Abstract

Mycobacterium tuberculosis has infected more than two billion individuals worldwide, of whom 5%-10% have clinically active disease and 90%-95% remain in the latent stage with a reservoir of viable bacteria in the macrophages for extended periods of time. The tubercle bacilli at this stage are usually called dormant, non-viable, and/or non-culturable microorganisms. The patients with latent bacilli will not have clinical pictures and are not infectious. The infections in about 2%-23% of the patients with latent status become reactivated for various reasons such as cancer, human immunodeficiency virus infection, diabetes, and/or aging. Many studies have examined the mechanisms involved in the latent state of Mycobacterium and showed that latency modified the expression of many genes. Therefore, several mechanisms will change in this bacterium. Hence, this study aimed to briefly examine the genes involved in the latent state as well as the changes that are caused by Mycobacterium tuberculosis. The study also evaluated the relationship between the functions of these genes.

Entities:  

Keywords:  Dormancy; Hypoxic Conditions; Latency; Mycobacterium tuberculosis; Tuberculosis

Year:  2020        PMID: 33121230     DOI: 10.4046/trd.2020.0116

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  2 in total

1.  In Silico Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis.

Authors:  Kirsten E Knoll; Mietha M van der Walt; Du Toit Loots
Journal:  Microbiol Spectr       Date:  2022-03-30

2.  Correlation between polymorphism of vitamin D receptor TaqI and susceptibility to tuberculosis: An update meta-analysis.

Authors:  Bin Li; Fei Wen; Zhaofen Wang
Journal:  Medicine (Baltimore)       Date:  2022-04-22       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.